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Abstract
Background Pompe disease is an orphan disease for which
enzyme replacement therapy (ERT) recently became avail-
able. This study aims to estimate all relevant aspects of
burden of illness—societal costs, use of home care and
informal care, productivity losses, and losses in health-
related quality of life (HRQoL)—for adult Pompe patients
only receiving supportive care.
Methods We collected data on all relevant aspects of
burden of illness via a questionnaire. We applied a societal
perspective in calculating costs. The EQ-5D was used to
estimate HRQoL.
Results Eighty adult patients (87% of the total Dutch adult
Pompe population) completed a questionnaire. Disease
severity ranged from mild to severe. Total annual costs
were estimated at €22,475 (range €0–169,539) per adult
Pompe patient. Patients on average received 8 h of home
care and 19 h of informal care per week. Eighty-five
percent of the patients received informal care from one or
more caregivers; 40% had stopped working due to their
disease; another 20% had reduced their working hours.
HRQoL for Pompe patients who only received supportive
care was estimated at 0.72, 17% lower than the Dutch
population at large.
Conclusions Adult Pompe disease is associated with a
considerable burden of illness at both the societal and
patient levels. The disease leads to substantial costs and
dependency on medical devices, home care, and informal
care, and has a high impact on the patient’s social network.
In addition, patients are limited in their ability to work and
have significantly reduced HRQoL.
Introduction
Pompe disease (glycogen storage disease type II; acid
maltase deficiency) is a neuromuscular and lysosomal
storage disorder caused by deficiency of the enzyme acid
alpha-glucosidase, which is required for the degradation of
lysosomal glycogen (Hirschhorn and Reuser 2001). Storage
of glycogen occurs mainly in skeletal muscles and leads to
loss of muscle function. The disease presents as a broad
clinical spectrum. The severe classic infantile form is
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of life (van der Ploeg and Reuser 2008; van den Hout et al.
2003; Kishnani et al. 2006). The majority of patients have a
more slowly progressive or “late-onset” form of the disease.
First symptoms may present from infancy to the sixth
decade of life. The vast majority of patients are adults.
Muscle weakness affects both mobility and respiratory
function, and most patients eventually become wheelchair-
bound or ventilator-dependent (van der Ploeg and Reuser
2008; Laforet et al. 2000; Hagemans et al. 2005).
Pompe disease is an orphan disease, which is defined in
Europe as a disease that affects fewer than 5 per 10,000
people and in the U.S. as a disease that affects fewer than
200,000 people. Pompe disease occurs with an estimated
frequency of approximately 1 in 40,000 births in the
Netherlands (Ausems et al. 1999) .S i m i l a ro rl o w e r
frequencies have been reported for other countries (Martiniuk
et al. 1998;M e i k l ee ta l .1999). Our study focuses on adult
Pompe disease patients, who make up about 80% of the
known Dutch patient population.
In2006thecommercialavailabilityofenzymereplacement
therapy (ERT) made Pompe disease the first inheritable
muscle disorder for which therapy is available (van den Hout
et al. 2000;K i s h n a n ie ta l .2007; van der Ploeg et al. 2010).
For a few other lysosomal storage disorders (Gaucher
disease, Fabry disease, mucopolysaccharidosis I, II, and
VI), similar therapies became available at earlier stages
(Barton et al. 1991; Eng et al. 2001; Schiffmann et al. 2001;
Kakkis et al. 2001; Harmatz et al. 2004). Costs of ERT in
Pompe disease are considerable, especially in adults,
averaging about €300,000 per patient annually. In the
Netherlands ERT for Pompe disease is conditionally reim-
bursed for a period of 3–4 years. Traditional cost-
effectiveness analysis is considered inappropriate for orphan
diseases because of their low frequencies and relatively high
developmental costs of treatment (Drummond et al. 2007).
Cost-effectiveness is, however, a topic that should be
addressed given the conditions of reimbursement of ERT.
Most cost of illness studies, often performed from a
societal perspective, fail to account for the entire burden of
an illness. Patients might need medical devices; they might
need home care and informal care (which can potentially
also affect patients’ families’ lives); patients’ capacity to
work could be limited; and any disease can affect patients’
health-related quality of life (HRQoL). A burden of illness
(BOI) study, which compiles all these aspects, has
heretofore been unavailable for adult Pompe disease
patients, although BOI of adults with Pompe disease is
expected to be substantial. Hence, the aim of this study is to
assess the burden of Pompe disease with respect to all
aspects: societal costs, the use of home care and informal
care, productivity losses, and losses in HRQoL. Following
Hagemans et al. (2004), quality of life is expected to be
lower for more severely affected patients, i.e., patients
using ambulatory or respiratory devices. These patients are
also expected to incur higher annual costs.
Methods
Study population
The Center for Lysosomal and Metabolic Diseases at
Erasmus Medical Center serves as the national referral
center for patients with Pompe disease. From January 2005
to October 2009, 92 adults with Pompe disease were seen at
Erasmus MC. This study focuses on patients that only
receive supportive care, i.e., costs of ERT are not assessed
in this study. Patients who completed one or more health
economic questionnaire(s) while only receiving supportive
care from January 2005 to October 2009 were included in
the sample.
Data collection
Aspartofalong-termfollow-upstudyonthenaturalcourseof
the disease, effects of ERT, and health economic aspects,
patients were asked to complete a health economic question-
naire every 6 months. All relevant aspects of BOI—medical
consumption (e.g., hospital admissions and day visits,
ambulatory care, medications, tests, use of medical devices),
use of informal care and home care, productivity losses due to
absence from work, reduced efficiency, and HRQoL—were
considered in the questionnaire. The part of the questionnaire
measuring health care utilization contained the most relevant
medical services for patients with Pompe disease. No
distinction was made between costs related to Pompe disease
and those not specifically related to Pompe disease. A similar
approach was taken for the assessment of productivity losses.
Data collection started in 2005 and is ongoing for both
patients receiving supportive care only and patients receiving
ERT. The study was approved by the Central Committee on
Research Involving Human Subjects in the Netherlands, and
participants provided written informed consent.
Medical costs
Costs were calculated following the Dutch guidelines for
costing studies (Oostenbrink et al. 2004). Individual costs
were obtained by multiplying volumes of components at
individual patient levels with relevant unit costs from the
costing manual (Oostenbrink et al. 2004). We adopted the
societal perspective, i.e., all relevant costs were included in
the analyses regardless of who incurred these costs
(Drummond et al. 2004). Home care was valued with wage
rates from the Dutch costing manual (Oostenbrink et al.
1046 J Inherit Metab Dis (2011) 34:1045–10522004). Medication prices were obtained from the Dutch
Pharmacotherapeutic Compass (Health Care Insurance
Board 2009). Market prices were used as unit prices for
medical equipment, medical devices, and home adjust-
ments. Unit costs are given in Table 1. Semi-annual costs
were calculated for each patient by taking the average costs
of all observations during the period when the patient did
not receive ERT. Semi-annual costs were then doubled to
obtain yearly costs per patient. Consumer price indices
were used to estimate all costs in 2009 euro values.
Nonmedical costs
Informal care
Informal care was valued using the shadow price method,
which uses professionals’ wage rates to valuate informal
caregivers’ time.
Productivity losses
Patients might be forced to reduce their working hours or
stop working altogether due to disability. The disease might
also lead to absences from work. All these aspects were
included in the analyses. Costs associated with productivity
losses were computed using the friction cost method as
recommended in the Dutch guidelines for costing studies
(Oostenbrink et al. 2004). In this approach, societal
production losses are limited to short-term productivity
losses. For absences longer than 22 weeks, an absent
employee is assumed to be replaced by a previously
unemployed person. The period required to hire and train
the new employee is called the friction period, which is the
only time associated with productivity costs (Koopman-
schap et al. 1995). For (international) comparison, we also
applied the human capital approach, which assumes that
productivity losses are generated until retirement (van den
Hout 2010). Wage rates, corrected for age and gender, were
obtained from the costing manual (Oostenbrink et al. 2004).
Health-related quality of life
HRQoL was assessed using the EQ-5D instrument, which
consists of five dimensions (mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression), each having
three levels (no limitations, some limitations, and severe
limitations).Whencombinedwithhealthstates“unconscious”
and“death”the instrumentdescribes 245 distinct healthstates.
Each health state is associated with a utility using a scoring
formula (Drummond et al. 2004). Utility scores were
estimated using the Dutch tariff (Lamers et al. 2006). As
such, utilities derived from health states can be regarded as a
valuation of that specific health state by the Dutch general
population. Utilities typically range from zero (death) to 1
(perfect health). Some health states correspond to negative
utilities, implying that these health states are regarded as
being worse than death (Lamers et al. 2006).
Statistical methods
Respiratory support and ambulatory support were used as
indicators of disease severity (Laforet et al. 2000;H a g e m a n s
et al. 2004, 2005). Changes in use of such support over time
were examined with McNemar’s test. Year of diagnosis was
used to determine disease duration. In comparing utilities
and costs, patients were categorized on the basis of their last
observation. Differences in utilities and total costs between
users and nonusers of ambulatory and respiratory support
were examined with Mann-Whitney tests. To examine
differences in utilities due to disease duration, patients were
Cost component Cost per unit
a (€) Source
Hospital care 394
b Oostenbrink et al. 2004
Intensive care 1,847 Oostenbrink et al. 2004
Nursing home 226 Oostenbrink et al. 2004
Ambulatory care
Hospital day visits 69
b Oostenbrink et al. 2004
GP visits 22 Oostenbrink et al. 2004
Physiotherapy 25 Oostenbrink et al. 2004
Other paramedical 14–91 Oostenbrink et al. 2004
Home care per hour 29–65 Oostenbrink et al. 2004
Medication Health Care Insurance Board 2009
Other medical costs
Tests and procedures 54–181 Oostenbrink et al. 2004
Respiratory support per day 5 Hoogendoorn et al. 2004
Medical devices 18–1,500 Market prices
Table 1 Medical cost compo-
nents and associated unit costs
(2009 prices)
aCosts per unit are based on
average unit costs for medical
procedures, consultations, and
admissions (Oostenbrink et al.
2004)
bWeighted average of academic
and general hospital costs
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these groups were examined using Kruskal-Wallis tests. The
level of significance for statistical tests was set at 5%. To
examine the relation between costs and HRQoL, a Spear-
man’s correlation was computed. Statistical analyses were
performed using Microsoft Excel 2003 (Microsoft, 2003)
and SPSS version 15.0 (SPSS, 2006).
Results
Patient population
Eighty adult Pompe patients (87% of the Dutch Pompe
population) completed at least one health economic
questionnaire while only receiving supportive care. In total,
161 questionnaires were completed. Patient characteristics
are presented in Table 2. The average baseline age of the
population was 51 years; half of the population was male.
The average disease duration at baseline was 9 years. The
number of patients using respiratory support and ambula-
tory support increased during the study, but not significant-
ly (McNemar’s P=1.000 and P=0.125, respectively,
Table 2). Background information on ambulatory and
respiratory support for the 12 patients who did not
participate in the study showed no significant differences
compared to participating patients.
Medical costs
Table 3 shows the volumes of medical consumption for adult
Pompe patients only receiving supportive care. Patients
annually made five outpatient hospital visits on average,
primarily to the neurologist (28%). Three patients lived
permanently in a nursing home due to Pompe disease. On
average, patients made two visits to the general practitioner.
Physiotherapy was the most frequently used type of paramed-
ical care, averaging 18 visits per patient annually, but its use
varied widely among patients. Half the population used
medication, taking four different medicines on average. Most
patients (70%) reported using medical devices, of which the
majority (75%) used more than one device (on average three
devices per patient). Most frequently used devices were
wheelchairs and other ambulatory support equipment.
Thirty-three percent of the patients used respiratory support.
Patients’ average need for home care was 8 h/week.
Table 3 also shows the distribution of costs of different
medical components. Annual medical costs per patient were
estimated at €13,679 (range €0–167,935). Home care,
associated with an annual cost of €7,011 (range €0–
85,987), was the largest medical cost component (51%).
Nursing home admissions—relevant for three patients—
accounted for 19% of medical costs. Respiratory support
was calculated by multiplying daily costs by 365 days and
the percentage of patients using the support. Respiratory
support accounted for average annual costs of €574 per
patient. Volumes are also presented in Table 3.
Nonmedical costs
Table 4 shows the indirect(nonmedical)costs associatedwith
Pompe disease for patients only receiving supportive care and
how these indirect costs relate to medical cost components.
Informal care
Patients on average received 19 h/week of informal care,
totaling €5,741 annually (range €0–36,037). Informal care
mostly comprised household activities such as cleaning and
grocery shopping (44%). Eighty-five percent of the patients
received informal care, in most cases from more than one
caregiver. Caregivers were most often the patient’s spouse
(76%),followedbychildren(34%),friends(18%),andparents
(16%).
Productivity losses
Thirty-nine percent of the patients (n=31) were employed,
52% of whom indicated they were working fewer hours
than they would have without the disease (average: 14 h
First questionnaire Last questionnaire
Number of patients
a 80 80
Demographic characteristics
Age (years; SD, min–max) 51.0 (± 12.2; 25–76) 51.9 (± 12.2; 25–76)
Gender (number, % male) 41 (51%) 41 (51%)
Clinical characteristics
Duration since diagnosis (years; SD, min–max) 9.3 (± 9.4; 0–30) 10.2 (± 9.3; 0–30)
Ambulatory support (%) 48.8% 55.0%
Respiratory support (%) 30.0% 32.1%
Table 2 Characteristics of the
study population
aFor patients who completed only
one questionnaire, it was used
both as first and last observation
1048 J Inherit Metab Dis (2011) 34:1045–1052fewer). In addition, 32% were absent from work due to
illness for an average of 12 work days. Thirty-two patients
(40%) indicated they stopped working due to Pompe
disease; 11 of them had been declared unfit for work.
Table 3 Average medical consumption and average costs per patient for adult Pompe patients only receiving supportive care
Respondents using
service, n (%)
Average units used
per patient, n (SD)
Average annual cost
per patient (€)( n=80)
Range of per patient
costs (€)
Hospital care 313 0–6,303
Patients hospitalized 12 (15)
Number of hospitalizations (if hospitalized) 2 (1.2)
Duration per hospitalization (nights) 4 (4.4)
Intensive care 808 0–18,467
Patients hospitalized 7 (9)
Number of hospitalizations (if hospitalized) 2 (1.1)
Duration (nights; if hospitalized) 5 (3.3)
Nursing home 3 (4) 2,571 0–82,454
Ambulatory care
Hospital day visits 71 (89) 5 (6.1) 372
GP visits 46 (58) 2 (1.9) 36
Physiotherapy 32 (40) 18 (39.2) 473
Other paramedical 27 (34) 4 (9.7) 162
Total costs 1,043 0–7,217
Home care 31 (39) 7,011 0–85,987
Home care (h/week) 8 (18.4)
Medication 198 0–1,257
Patients on medication 42 (53)
Number of medicines (if on medication) 4 (3.8)
Other medical costs
Tests and procedures 71 (89) 7 (4.3) 750
Respiratory support 26 (33) 574
Medical devices 56 (70) 411
Number of devices (if using devices) 3 (2.0)
Total costs 1,735 0–5,020
Overall 13,679 0–167,935
Cost category Average per patient cost (€) Ranges of per patient costs (€)
Hospital days 313 0–6,303
Intensive care 808 0–18,467
Nursing home 2,571 0–82,454
Ambulatory care 1,043 0–7,217
Home care 7,011 0–85,987
Medication 198 0–1,257
Other medical costs
a 1,735 0–5,020
Total medical costs 13,679 0–167,935
Informal care 5,741 0–36,037
Transportation 158 0–1,918
Productivity losses 2,633 0–38,176
Other nonmedical costs 263 0–7,032
Total nonmedical costs 8,796 0–46,992
Overall 22,475 0–169,539
Table 4 Estimated annual costs
of Pompe disease per adult
patient
aIncluding tests, procedures, res-
piratory support, medical devices
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estimated at €2,633 (range €0–38,176) per patient per year.
Using the human capital approach to assess productivity
losses, average annual costs accumulated to €40,590 (±
45,574), 51% of which were due to productivity losses.
Total productivity losses until retirement would accumulate
to over €200,000 per patient.
Total costs for adult Pompe patients only receiving
supportivecareaccumulated to€22,475 per year (range €0–
169,539). Medical costs accounted for 61% of total annual
costs. The largest cost components were home care (31%),
informal care (26%), and productivity losses (12%).
Health-related quality of life
Seventy-two patients (78% of the Dutch adult Pompe
population only receiving supportive care) completed the
EQ-5D. Table 5 shows the HRQoL of patients with Pompe
disease subdivided by disease duration, ambulatory sup-
port, and respiratory support. The average utility for Pompe
patients was 0.72, whereas the mean utility for a represen-
tative sample of the Dutch population has been estimated at
0.87 (Stolk et al. 2009). The utility decrement as a
consequence of Pompe disease of 0.15 was significant.
Adult Pompe patients had a 17% lower utility than an
average Dutch person. The decrement resulted mainly from
mild limitations in the domains of mobility, usual activities,
and pain. Severe limitations were only observed in a limited
number of cases.
Disease severity was determined on the basis of the
use of ambulatory and respiratory support. Patients using
ambulatory and respiratory support reported lower
HRQoL compared to patients without such devices, but
the differences were not significant. In contrast, total
costs were significantly higher for patients using ambu-
latory and/or respiratory devices. Longer disease duration
resulted in higher annual costs. The association between
disease duration and total annual costs or utilities was
not significant. As expected, total annual costs per
patient were significantly negatively correlated with
HRQoL (rho = −0.534).
Discussion
This is the first burden of illness study of adults with Pompe
disease. The study shows that the disease poses a substantial
burdenonpatients,their families,andsocietyinterms ofcosts
of illness, use of medical devices, home care and informal
care, productivity losses, and HRQoL. Costs due to Pompe
disease for patients that only receive supportive care amount
toanaverageof€22,475 per patient annually, ranging from €0
to 169,539. Besides costs to society, patients’ daily lives are
substantially affected. Indicative is the large number of hours
of support patients require from professionals and their social
environment. Home care is used on average 8 h/week per
patient and accounts for 31% of total annual costs. In addition,
patients require 19 h/week of informal care, accounting for
26% of annual costs. Eighty-five percent of the patients
receive informal care from one or more caregivers, indicating
that the disease also has an important impact on the patient’s
social network. Most patients (70%) use medical devices; the
majority (75%) of those patients use more than one device.
The impact on productivity is considerable. Forty percent of
the adult Pompe patients had stopped working due to their
disease; another 20% had reduced the number of working
hours. Six patients (19% of working patients) indicated they
wouldhaveappliedforajobatahigherfunctionallevelifthey
had not been affected by the disease. The study also shows
that HRQoL for patients is estimated at 0.72, an average 17%
lower than the Dutch population at large. Lower utilities were
associated with higher patient costs.
The highest costs were incurred by patients living in
nursing homes with utilities below 0.4 and involved
severely affected patients who were both ventilator- and
wheelchair-dependent. Only one 20-year-old male patient
had zero costs and a utility of 1.
There were no data available on medical costs associated
with MRI and DNA testing and home mechanical ventila-
tion. Consequently, medical costs could have been under-
estimated. In addition, 58% of the working patients
indicated they would be more efficient (on average 32%)
absent their disease. For some of the patients who had
stopped working, corresponding productivity losses could
Number (%) EQ-5D utility score (SD) Number (%) Total costs (€)
Overall (SD; min–max) 72 0.72 (0.18; 0.17–1.00) 80 22,475
Disease duration
≤5 years 31 (43) 0.74 (0.15) 33 (42) 13,922
6–15 years 18 (25) 0.70 (0.16) 19 (24) 26,290
>15 years 22 (31) 0.69 (0.23) 27 (34) 30,736
Ambulatory support 37 (51) 0.67 (0.21) 44 (55) 33,246
Respiratory support 20 (28) 0.61 (0.26) 25 (32) 41,485
Table 5 HRQoL and total costs
for adult Pompe patients only
receiving supportive care
1050 J Inherit Metab Dis (2011) 34:1045–1052not be estimated due to lack of data; productivity losses are
thus underestimated.
As recommended by the Dutch guidelines for costing
studies (Oostenbrink et al. 2004), we applied the friction
cost method as the primary approach to assess productivity
costs in Pompe patients. Average productivity costs using
this method are €2,633 (range €0–38,176) per patient per
year, but would have been substantially higher (€40,590 per
patient per year; range €0–224,205) had we used the human
capital approach. As Pompe disease is a chronic condition,
the large difference between the estimates is caused by
absence from work due to the disease for a period longer
than 22 weeks, which is not associated with costs using the
friction cost method. Koopmanschap et al. (1995)a r g u e
that the friction cost method is the most realistic approach
to value productivity losses in terms of societal costs since
a person unable to work for a period of more than 22 weeks
will be replaced.
Due to the relatively small number of patients, the
uncertainty surrounding the estimates is large, as revealed by
the broad ranges of costs and HRQoL estimates. Excluding
the three patients permanently living in a nursing home
reduced the average annual costs per patient by €3,435
(standard deviation 23%). The impact of the three patients
ontotalcostsandstandarderrorsreflectsthemajorproblemof
dealingwitha small patient populationina rareillness suchas
Pompe disease. This study used information over a period of
almost 5 years instead of 1 to increase the number of
observations. Such an approach—averaging all observations
per patient to enlarge the study population—can be used as a
tool to investigate the burden of illness in other rare diseases.
For adult Pompe patients only receiving supportive care,
costs associated with informal care and productivity losses
account for 26 and 12% of total annual costs of €22,475,
respectively. In comparison, total medical and nonmedical
annual costs for Dutch patients with multiple sclerosis have
been estimated at €17,450 (2009 prices), with productivity
losses estimated at 4–5% and informal care about 21%
(Kobelt et al. 2006) of the total. For patients suffering from
rheumatoid arthritis, informal care and productivity losses
have been estimated at 25 and 18% of total annual costs,
respectively (Franke et al. 2009). For the Netherlands no
cost of illness study was available for a neuromuscular
disorder similar to Pompe disease. For the U.S., total annual
medical costs for children and young adults with muscular
dystrophy were estimated at €18,250 (conversion rate $1=
€0.822; 2009 prices). Costs of informal care and produc-
tivity losses were not provided in this study (Ouyang et al.
2008). Transferability of cost of illness estimates is
generally limited due to specifics of national health care
systems (Drummond et al. 2005). To increase transparency
of the results, volumes and unit costs are also presented in
Tables 1 and 3.
For adult Pompe patients who only receive supportive
care, HRQoL is 0.72. By comparison, hearing complaints
have been associated with an HRQoL of 0.86 (Grutters et
al. 2007), and multiple sclerosis with an HRQoL of 0.61
(Kobelt et al. 2006). These figures represent average levels
of HRQoL. Large variations in disease severity, however,
make HRQoL comparisons between different diseases
difficult.
Here we have focused on adult Pompe patients who only
receive supportive care. Future studies will similarly
examine the burden of illness for adult Pompe patients
receiving enzyme therapy to evaluate the cost-effectiveness
of enzyme replacement therapy.
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